Evidence map›Paper›PMID 40467515›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Corticosteroid-induced Cushingoid Appearance in Myasthenia Gravis.

Akiyuki Uzawa, Shigeaki Suzuki, Satoshi Kuwabara, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yukiko Ozawa, Naoki Kawaguchi, Tomoya Kubota, Masanori P Takahashi and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Akiyuki UzawaDepartment of Neurology, Graduate School of Medicine, Chiba University, Japan.
Shigeaki SuzukiDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Japan.
Satoshi KuwabaraDepartment of Neurology, Graduate School of Medicine, Chiba University, Japan.
Manato YasudaDepartment of Neurology, Graduate School of Medicine, Chiba University, Japan.
Hiroyuki AkamineDepartment of Neurology, Graduate School of Medicine, Chiba University, Japan.
Yosuke OnishiDepartment of Neurology, Graduate School of Medicine, Chiba University, Japan.
Yukiko OzawaDepartment of Neurology, Graduate School of Medicine, Chiba University, Japan.
Naoki KawaguchiDepartment of Neurology, Neurology Chiba Clinic, Japan.
Tomoya KubotaDepartment of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, The University of Osaka Graduate School of Medicine, Japan.
Masanori P TakahashiDepartment of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, The University of Osaka Graduate School of Medicine, Japan.
Yasushi SuzukiDepartment of Neurology, National Hospital Organization Sendai Medical Center, Japan.
Genya WatanabeDepartment of Neurology, National Hospital Organization Sendai Medical Center, Japan.
Takashi KimuraDepartment of Neurology, Hyogo Medical University, Japan.
Takamichi SugimotoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University, Japan.
Makoto SamukawaDepartment of Neurology, Kindai University Faculty of Medicine, Japan.
Naoya MinamiDepartment of Neurology, National Hospital Organization Hokkaido Medical Center, Japan.
Masayuki MasudaDepartment of Neurology, Tokyo Medical University, Japan.
Shingo KonnoDepartment of Neurology, Toho University Ohashi Medical Center, Japan.
Yuriko NaganeDepartment of Neurology, Hanamaki General Hospital, Japan.
Kimiaki UtsugisawaDepartment of Neurology, Hanamaki General Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Corticosteroids are the primary immunosuppressants used to treat myasthenia gravis (MG). Their side effects, including Cushingoid appearance, are well documented. However, the precise relationship between corticosteroid usage and Cushingoid appearance has not been fully explored. Methods This study investigated the frequency and severity of Cushingoid appearance and their relationships with corticosteroid use. In total, 1,321 consecutive patients with MG who were prednisolone users, enrolled in the Japanese MG registry study 2021, were examined, and the severity of Cushingoid appearance was evaluated using the Cushingoid appearance index. Results The rates of Cushingoid appearance at survey and peak were 36.4% and 62.0%, respectively. Multivariate regression analyses revealed that the current Cushingoid appearance index was correlated with the current prednisolone dose, duration of prednisolone dose >10 mg/day, and female sex. The risk of Cushingoid appearance was classified according to prednisolone dose and duration using a decision tree. The Cushingoid appearance index significantly decreased with decreases in the prednisolone dose during the 6 years of follow-up. The Cushingoid appearance index was also significantly correlated with the MG-Quality of Life 15-revised score. Conclusion This study elucidated the relationship between corticosteroid treatment and Cushingoid appearance in MG, suggesting that the high-dose and long-term use of corticosteroids should be avoided to improve the patient quality of life.

Indexed as

Adrenal Cortex HormonesImmunosuppressive AgentsMyasthenia GravisPrednisoloneAdultAgedDose-Response Relationship, DrugFemaleHumansJapanMaleMiddle AgedQuality of LifeRegistriesSeverity of Illness IndexAdrenal Cortex HormonesImmunosuppressive AgentsPrednisoloneCushingoid appearancemoon facemyasthenia gravisprednisolonequality of life

Identifiers

PMID40467515
PMCPMC12804444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.